

This communication should be viewed by:
 Facility/Practice staff
 Clinical staff

Pharmacy Formulary Updates Effective April 1, 2023

The MVP Health Care® (MVP) Pharmacy and Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require prior authorization for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at mvphealthcare.com.

New Drugs (prior authorization required)

Drug Name	Indication	Commercial and Marketplace Tier	MVP Medicaid	Medicare Part D tier
Terlivaz ® (terlipressin)	The improvement of kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function	Medical	Medical	Medical
Imjudo ® (tremelimumab)	The treatment of unresectable hepatocellular carcinoma in adults, in combination with Imfinzi (durvalumab)	Medical	Medical	Medical Part D- Tier 5 if RxCUI becomes available
Tecvayli ™ (teclistamab-cqyv)	The treatment of relapsed or refractory multiple myeloma in adults who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody	Medical	Medical	Tier 5
Lytgobi ® (futibatinib)	The treatment of adults with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements	Tier 3 and oral chemo copay	Tier 3/Non-formulary	Tier 5
Elahere ™ (mirvetuximab)	The treatment of patients with folate receptor alpha high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 systemic treatments	Medical	Medical	Medical, Part D- Tier 5 if RxCUI becomes available
Tzield ™ (teplizumab-mzwv)	The delay of clinical type 1 diabetes in at-risk adults and pediatric patients aged 8 years and older	Prior Authorization per Tzield policy, Medical	Prior Authorization per Tzield policy, Medical	Medical
Rezlidhia ™ (olutasidenib)	The treatment of relapsed or refractory acute myeloid leukemia in patients with an IDH1 mutation	Tier 3 and oral chemo copay	Tier 3/Non-formulary	Tier 5

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



Hemgenix® (etranacogene dezaparvovec)	The treatment of hemophilia B in adults who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.	Medical	Medical	Medical
Furoscix® (furosemide controlled release on-body infusor)	The treatment of chronic heart failure	Tier 3	Tier 3/Non-formulary	Nonformulary
Xelstrym™ (dextroamphetamine)	The treatment of attention deficit hyperactivity disorder in patients aged 6 years and older	Tier 3	Tier 3/Non-formulary	Nonformulary
Basaglar® Tempo Pen™ (insulin glargine)	Tempo Pen™ is a part of Personalized Diabetes Management Platform from Lilly - Prefilled, disposable pen compatible with multiple Lilly insulins; Functions similarly to a Lilly KwikPen®; Can be used on its own or with the Tempo Smart Button* once available	Tier 3	Tier 3/Non-formulary	Nonformulary
Humalog Tempo Pen™ (insulin lispro)	Tempo Pen™ is a part of Personalized Diabetes Management Platform from Lilly - Prefilled, disposable pen compatible with multiple Lilly insulins; Functions similarly to a Lilly KwikPen®; Can be used on its own or with the Tempo Smart Button* once available	Tier 3	Tier 3/Non-formulary	Nonformulary
Lyumjev Tempo Pen™ (insulin lispro)	Tempo Pen™ is a part of Personalized Diabetes Management Platform from Lilly - Prefilled, disposable pen compatible with multiple Lilly insulins; Functions similarly to a Lilly KwikPen®; Can be used on its own or with the Tempo Smart Button* once available	Tier 3	Tier 3/Non-formulary	Nonformulary
Ermeza™ (levothyroxine)	The replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer	Tier 3	Tier 3/Non-formulary	Tier 4

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

